SG
OTLK icon

StoneX Group’s Outlook Therapeutics OTLK Stock Holding History

StoneX Group’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.7K Buy
+13,122
New +$5.67K ﹤0.01% 898

Other funds holding OTLK

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GWM
Gilpin Wealth Management Denver, Colorado $126M AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
NMC
Nine Masts Capital Central, Hong Kong $693M AUM 31.93% 1-Year Est. Return
CCM
Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return

StoneX Group's OTLK Position: Q1 2026 in Review

StoneX Group opened a new position in Outlook Therapeutics (OTLK) in Q1 2026: 13,122 shares worth $2.7K. The stake represents ﹤0.01% of the portfolio and ranks #898 among its holdings.

54 funds tracked by Wall St. Rank hold OTLK as of Q1 2026.

  • StoneX Group held 13,122 shares of Outlook Therapeutics worth $2.7K as of Q1 2026.
  • Outlook Therapeutics was a new StoneX Group position in Q1 2026.
  • Outlook Therapeutics made up ﹤0.01% of StoneX Group's portfolio in Q1 2026, its #898 holding.
  • 54 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q1 2026.

Based on StoneX Group's 13F filing for Q1 2026, filed 14 May 2026.